Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 14/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.55 |
| ▸ | SRC | P12931 | 6/20 | 0.55 |
| ▸ | WEE1 | P30291 | 4/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657548 | 0.93 | FGFR1 (0.55) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL14573081 | 0.86 | WEE1 (0.56) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5660213 | 0.83 | FGFR1 (0.51) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL4414757 | 0.83 | EGFR (0.47) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5583940 | 0.82 | ABL1 (0.47) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5583960 | 0.81 | FGFR1 (0.48) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL28562488 | 0.79 | RIPK2 (0.47) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5583941 | 0.78 | SRC (0.63) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5583963 | 0.78 | SRC (0.66) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5583802 | 0.77 | ABL1 (0.61) | FGFR1FGFR2FGFR4FGFR3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007529451-A | — | — | 2007-10-25 | — | — | JP | claimed |
| US-7189732-B2 | Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | claimed |
| EP-1727819-A1 | NOVEL DICHLORO-PHENYL-PYRIDO¬2,3-D|PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | claimed |
| US-20060014765-A1 | Dichloro-phenyl derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-19 | — | — | US | claimed |
| WO-2005090344-A1 | NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014002110-A1 | SUBSTITUTUED PYRAZOLE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF. | RALLIS INDIA LIMITED (IN) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-7189732-B2 | Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1727819-A1 | NOVEL DICHLORO-PHENYL-PYRIDO¬2,3-D|PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | disclosed |
| US-20060014765-A1 | Dichloro-phenyl derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005090344-A1 | NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | FGFR1 482/4885FGFR2 1221/4885FGFR4 1521/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | FGFR1 358/4885FGFR2 914/4885FGFR4 1253/4885 |
| US-20060014765-A1 | Dichloro-phenyl derivatives | SRC, ABL1, LCK | FGFR1 145/4885FGFR2 159/4885FGFR4 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.